Abstract
The syndrome dementia is defined by evidence of a decline in memory, thinking, and emotional functions. In this article, dementia is delimited only by its symptoms; the etiology, the course, and the extensiveness of the disorder are not used as criteria of a dementia syndrome. In the descriptive diagnoses of dementia disorders, however, different aspects of the disorders are used. Descriptive diagnoses are (a) benign senile forgetfulness, (b) primary degenerative disorders, (c) secondary dementias, (d) cerebrovascular disorders with dementia, (e) reversible dementias, and (f) dementias with unknown etiology. Primary degenerative disorders include the subgroups (a) senile dementia of Alzheimer type (SDAT), (b) Alzheimer’s disease (AD), (c) Pick’s disease, and (d) Huntington’s chorea. The question whether SDAT and AD should be included in one group is discussed. Very interesting and stimulating treatment research is going on in the field of dementias. Although there has still been no real breakthrough, some results indicate that dementia symptoms may be influenced by treatment. At present, treatment strategies go along the following lines: (a) pharmacological treatment, (b) control of sleep apneas and circulatory disturbances, (c) brain tissue transplantation, and (d) psychotherapy and mental activation. The pharmacological manipulation of dementia disorders focuses on substituting failing neurotransmitter systems. The use of nootropic drugs and gangliosides is still at an experimental level. Findings of vitamin B12 deficiency in late-onset dementia make vitamin B12 substitution relevant. White matter disturbances such as incomplete infarctions are reported in brains from demented patients. Coincident findings of increased sleep apneas with severe hypoxemia make studies of circulatory disturbances of interest. Transplantation of brain tissue has already left the animal experimental level and been applied to patients with parkinsonism. In some investigations, it is shown that mental activation causes not only a mental improvement but also changes in cerebrospinal fluid indicating the stimulation of trophic factors.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adolfsson R, Gottfries CG, Oreland L, Wiberg Å, Winblad B (1980) Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci 27: 1029–1034
Branconnier RJ, Cole JO, Dessain EC, Spera KF, Ghazvinian S, DeVitt D (1983) The therapeutic efficacy of pramiracetam in Alzheimer’s disease: Preliminary observations. Psychophar- macol Bull 19: 276
Bråne G (1986) Normal aging and dementia disorders — coping and crisis in the family. Prog Neuropsychopharmacol Biol Psychiatry 10: 287–295
Brun A, Gustafson L (1976) Distribution of cerebral degeneration in Alzheimer’s disease. A clinico-pathological study. Arch Psychiatr Nervenkr 223: 15–33
Carlsson A (1986) Neurotransmitters in old age and dementia. In: Hafner H, Moschel G, Sartorius N (eds) Mental health in the elderly: A review of the present state of research. Springer, Berlin Heidelberg New York
Gottfries CG (1983) Dementia. In: Hippius H, Winokur G (eds) Clinical psychopharmacology. Excerpta Medica, Amsterdam, pp 271–285 (Psychopharmacology, vol 1/2)
Gottfries CG (1986) Nosological aspects of differential typology of dementia of Alzheimer type. In: Bergener M (ed) Dimensions in aging. Academic, London, pp 207–219
Gottfries CG, Adolfsson R, Aquilonius SM, Carlsson A, Eckernäs SE, Nordberg A, Oreland L, et al. (1983) Biochemical changes in dementia disorders of Alzheimer type ( AD/SDAT ). Neurobiol Aging 4: 261–271
Gottfries CG, Karlsson I, Svennerholm L (1985) Senile dementia — A white matter disease? In: Gottfries CG (ed) Normal aging, Alzheimer’s disease and senile dementia. Aspects on etiology, pathogenesis, diagnosis and treatment. Éditions de L’Université de Bruxelles, Bruxelles, pp 111–118
Itil TM, Menon GN, Bozak M, Songar A (1982) The effects of oxiracetam (ISF 2522) in patients with organic brain syndrome (a double-blind controlled study with piracetam). Drug Dev Res 2: 448
Karlsson I, Widerlöv E, Melin EV, Nyth AL, Bràne GAM, Rybo E, Rehfeld JF, Bissette G, Nemeroff CB (1985) Changes of CSF neuropeptides after environmental stimulation in dementia. Nord Psykiatr Tidsskr [Suppl 11] 49: 75–81
Loew DM, van Deusen EB, Meier-Ruge W (1978) Effect on the central nervous system. In: Berde B, Schild HO (eds) Ergot alkaloids and related compounds. Springer, Berlin Heidelberg New York, pp 421–531 (Handbook of experimental pharmacology, vol 49 )
Mayeux R, Stern Y, Spanton S (1985) Heterogeneity in dementia of the Alzheimer type. Evidence of subgroups. Neurology (NY) 35: 453–461
Nyberg P, Nordberg A, Wester P, Winblad B (1983) Dopaminergic deficiency is more pronounced in putamen than in nucleus candatus in Parkinson’s disease. Neurochem Pathol 1: 193–202
Pearce J (1974) Mental changes in parkinsonism (letter). Br Med J 1: 445
Regland B, Gottfries CG, Oreland L, Svennerholm L (1988) Low B12 levels related to high activity of platelet MAO in patients with dementia disorders. A retrospective study. Acta Psychiatr Scand (Accepted for publication)
Rossor MN, Iversen LL, Reynolds GP, Mountjoy CQ, Roth M (1984) Neurochemical characteristics of early and late onset types of Alzheimer’s disease. Br Med J 288: 961–964
Sjögren T, Sjögren H, Lindgren AGH (1952) Morbus Alzheimer and morbus Pick. A genetic clinical and patho-anatomical study. Acta Psychiatr Neurol Sand [Suppl] 82
Sourander P, Sjögren H (1970) The concept of Alzheimer’s disease and its clinical implications. In: Wolstenholme GEW, O’Connor M (eds) Alzheimer’s disease and related conditions. Churchill, London, pp 11–36
Sourander L, Polo O, Alihanka J (1985) Sleep apnea and hypoxia in patients with senile dementia. Nordic Psychiatric Congress, 29 May-1 June
Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A (1986) Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 315: 1241–1245
Svennerholm L, Gottfries CG, Karlsson I (1987) Neurochemical changes in white matter of patients with Alzheimer’s disease. In: NATO Conference on multidisciplinary approach to myeline diseases. ( In press )
Zawadski RT, Glazer GB, Lurie E (1978) Psychotropic drug use among institutionalized and non-institutionalized medicaid aged in California. J Gerontol 33: 825–834
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Gottfries, C.G. (1988). Dementia: Classification and Aspects of Treatment. In: Casey, D.E., Christensen, A.V. (eds) Psychopharmacology: Current Trends. Psychopharmacology Series, vol 5. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73280-5_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-73280-5_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73282-9
Online ISBN: 978-3-642-73280-5
eBook Packages: Springer Book Archive